LAVAL,
QC, March 30, 2023 /PRNewswire/ -- Acasti
Pharma Inc. ("Acasti" or the "Company") (NASDAQ:
ACST) a late-stage, specialty pharma company advancing three
clinical stage drug candidates addressing rare and orphan diseases,
today announced that Mr. Jean-Marie (John)
Canan had tendered his resignation from the Board of
Directors of the Company, such resignation to take effect
immediately.
The Company's board of directors would like to thank Mr. Canan
for his contributions and wishes him every success in his future
endeavors.
About Acasti
Acasti is a late-stage specialty pharma company with drug
delivery technologies and drug candidates addressing rare and
orphan diseases. Acasti's novel drug delivery technologies have the
potential to improve the performance of currently marketed drugs by
achieving faster onset of action, enhanced efficacy, reduced side
effects, and more convenient drug delivery—all which could help to
increase treatment compliance and improve patient outcomes.
Acasti's three lead clinical assets have each been granted Orphan
Drug Designation by the FDA, which provide the assets with seven
years of marketing exclusivity post-launch in the United States, and additional intellectual
property protection with over 40 granted and pending patents.
Acasti's lead clinical assets target underserved orphan diseases:
(i) GTX-104, an intravenous infusion targeting Subarachnoid
Hemorrhage (SAH), a rare and life threatening medical emergency in
which bleeding occurs over the surface of the brain in the
subarachnoid space between the brain and skull; (ii) GTX-102, an
oral mucosal spray targeting Ataxia-telangiectasia (A-T), a
progressive, neurodegenerative genetic disease that primarily
affects children, causing severe disability, and for which no
treatment currently exists; and (iii) GTX-101, a topical spray
targeting Postherpetic Neuralgia (PHN), a persistent and often
debilitating neuropathic pain caused by nerve damage from the
varicella zoster virus (shingles), which may persist for months and
even years.
For more information, please
visit: https://www.acasti.com/en.
Forward-Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking information"
within the meaning of Canadian securities laws and "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, as amended, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (collectively, "forward
looking statements"). Such forward looking statements involve known
and unknown risks, uncertainties, and other unknown factors that
could cause the actual results of Acasti to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements containing the terms
"believes," "belief," "expects," "intends," "anticipates,"
"potential," "should," "may," "will," "plans," "continue",
"targeted" or other similar expressions to be uncertain and forward
looking. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. The forward-looking statements in this press release
are based upon Acasti's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Acasti undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as required by applicable securities laws. The NASDAQ
accepts no responsibility for the adequacy or accuracy of this
release.
Acasti Contact:
Jan D'Alvise
Chief Executive Officer
Tel: 450-686-4555
Email:info@acasti.com
www.acasti.com
Investor Relations:
Robert Blum
Lytham Partners, LLC
602-889-9700
ACST@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acasti-pharma-inc-announces-the-resignation-of-a-director-301785452.html
SOURCE Acasti Pharma Inc.